[Corrected]

---
identifier: "/us/fr/2019-10399"
source: "fr"
legal_status: "authoritative_unofficial"
title: "[Corrected]"
title_number: 0
title_name: "Federal Register"
section_number: "2019-10399"
section_name: "[Corrected]"
positive_law: false
currency: "2019-05-18"
last_updated: "2019-05-18"
format_version: "1.1.0"
generator: "[email protected]"
agency: "DEPARTMENT OF HEALTH AND HUMAN SERVICES"
document_number: "2019-10399"
document_type: "rule"
publication_date: "2019-05-18"
agencies:
  - "DEPARTMENT OF HEALTH AND HUMAN SERVICES"
  - "Food and Drug Administration"
cfr_references:
  - "21 CFR Part 886"
---


#  [Corrected]

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Final classification action; correction.

**SUMMARY:**

The Food and Drug Administration (FDA) is correcting a document that appeared in the *Federal Register* of April 12, 2019. That document was published with the instruction to add a section to the incorrect subpart. This correction is being made to improve the accuracy of the final classification action.

**DATES:**

Effective May 20, 2019, and applicable May 13, 2019.

**FOR FURTHER INFORMATION CONTACT:**

Lisa Granger, Office of Policy and Planning, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993, 301-796-9115.

**SUPPLEMENTARY INFORMATION:**

In FR Doc. 2019-07290 appearing on page 14865 in the *Federal Register* of Friday, April 12, 2019, the following correction is made:

§ 886.4355

**21 CFR Part 886**

1. On page 14870, in the second column, in part 886, amendatory instruction 11 is corrected to read as follows:

“11. “Add § 886.4355 to subpart E to read as follows:”

Dated: May 14, 2019.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.